Founded in 2011, Neurolixis is a San Diego-based biopharmaceutical company dedicated to developing innovative treatments for central nervous system diseases. The company's core mission is to address unmet medical needs in psychiatric and neurological disorders through the development of novel chemical entities. Neurolixis focuses on advancing compounds in both clinical and preclinical phases, with lead assets targeting movement disorders and autism spectrum disorders.
Key figures affiliated with Neurolixis include Mark A. Varney and Adrian Newman-Tancredi, who play pivotal roles in steering the company's research and development efforts. The company has made significant strides in its pipeline, with promising clinical and preclinical assets that have the potential to impact the treatment landscape for central nervous system diseases. Neurolixis's innovative approach and commitment to addressing critical health challenges underscore its growing influence in the biopharmaceutical industry.
